Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in bangladesh: An open-label randomized, controlled clinical trial

Journal of Infectious Diseases

Volumn 202, Issue 3, 2010, Pages 392-398

  Thriemer, Kamala ^a,b   Starzengruber, Peter ^a,b   Khan, Wasif Ali ^d   Haque, Rashidul ^d   Marma, Aung Swe Prue ^c   Ley, Benedikt ^a,b   Vossen, Matthias G ^a,b   Swoboda, Paul ^a,b   Akter, Jasmin ^d   Noedl, Harald ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Malaria Research Initiative Bandarban (MARIB)   (Bangladesh)

^c Bandarban Sadar Hospital   (Bangladesh)

^d ICDDR B Centre for Health and Population Research   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; AZITHROMYCIN; DIHYDROARTEMISININ; DOMPERIDONE; METOCLOPRAMIDE; OMEPRAZOLE; PARACETAMOL; PROTEIN HISTIDINE KINASE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BANGLADESH; BLOOD SMEAR; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; GAMETOCYTE; HEADACHE; HUMAN; HUMAN CELL; IC 50; KAPLAN MEIER METHOD; LOOSE FECES; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; PARASITE EXAMINATION; PARASITE PREVALENCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; REPEATED DRUG DOSE; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS; ANIMAL; DRUG COMBINATION; MIDDLE AGED; PARASITEMIA; TIME;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIMALARIALS; ARTEMISININS; AZITHROMYCIN; BANGLADESH; CHILD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954729556     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653710     Document Type: Article

References (30)

1. World Health Organization (WHO). World Malaria Report 2005. Geneva: WHO. http://rbm.who.int/wmr2005/profiles/bangladesh.pdf. Accessed 6 March 2008.
2. Noedl H, Krudsood S, Chalermratana K, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodiun falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 2006; 43:1264-1271.
3. Noedl H, Krudsood S, LeowattanaW, et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother 2007; 51: 651-656.
4. Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2002; 46:2518-2524.
5. Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26:146-150.
6. Taylor W, Richie T, Fryauff D, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999; 28:74-81.
7. Dunne MW, Singh N, Shukla M, et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 2005; 191:1582-1588. (Pubitemid 40656745)
8. Miller RS, Wongsrichanalai C, Buathong N, et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycinquinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg 2006; 74:401-406.
9. Heppner DG Jr, Walsh DS, Uthaimongkol N, et al. Randomized, controlled double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in western Thailand. Am J Trop Med Hyg 2005; 73:842-849.
10. Gray RH, Wabiwire-Mangen F, Kigozi G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Raiki, Uganda. Am J Obstet Gynecol 2001; 185(5):1209-1217.
11. Snounou G, Beck H. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998; 14:462-467.
12. World Health Organization (WHO). Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Document WHO/HTM/RBM/2003.50.2003, Geneva: WHO.
13. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg 2004; 71:711-714.
14. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother 2005; 49:3575-3577.
15. Na-Bangchang K, Kanda T, Tipawangso P, et al. Activity of artemetherazithromycin versus artemether-doxycycline in the treatment of mul398 • JID 2010:202 (1 August) • Thriemer et al tiple drug resistant falciparum malaria. Southeast Asian J Trop Med Public Health 1996; 27:522-525.
16. Sykes A, Hendriksen I, Mtove G, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 2009; 49:1195-1201.
17. Zithromax® [package insert]. Pfizer, 1999.
18. Lell B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 2002; 46: 2315-2320.
19. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-2620.
20. Thriemer K, Haque R, Wagatsuma Y, et al. Therapeutic efficacy of quinine plus sulfadoxine-pyremethamine for the treatment of uncomplicated falciparum malaria in Bangladesh. Am J Trop Med Hyg 2006; 75:645-649.
21. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe illness in Tanzania: a prospective study. BMJ 2004; 329:1212.
22. Frenck RW Jr, Mansour A, Nakhla I, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004; 38:951-957.
23. Noedl H. ABC-antibiotics-based combinations for the treatment of severe malaria? Trends Parasitol 2009; 25(12):540-544.
24. Newton P, Suputtamongkol Y, Teja-Isavadharm P, et al. Antimalarial Bioavailabiltiy and Disposition of Artesunate in Acute Falciparum Malaria. Antimicrob Agents Chemother 2000; 44(4):972-1927
25. Flatz G, Saengudom CH, Sanguanbhokhai T. Lactose intolerance in Thailand. Nature 1969; 221:758-759.
26. Wang Y, Yan Y, Xu J, et al. Prevalence of primary adult lactose malabsorption in three populations of northern China. Hum Genet 1984; 67:103-106.
27. Surjono A, Sebodo T, Soenarto J, Moenginah PA. Lactose intolerance among healthy adults. Pediatr Indonesia 1973; 13:49-54.
28. Asmawi MZ, Seppo L, Vapaatalo H, Korpela R. Hypolactasia and lactose intolerance among three ethnic groups in Malaysia. Indian J Med Res 2006; 124:697-704.
29. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697-704.
30. Ashley EA, Stepniewska K, Lindegardh N, et al. How much fat is necessary to optimize lumefantrine bioavailability? Trop Med Int Health 2007; 12(2):195-200.